5151 - 5175 of 9145 Results
Title
Year
- Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action2022OPENTitle: Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to ActionJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 4Start Page: 1359End Page: 1363Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-223190Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd223190?id=journal-of-parkinsons-disease%2Fjpd223190Citation Count: 15
- Baseline-dependency: How genotype and signaled delays influence amphetamine's effects on delay discounting2020RESTRICTEDTitle: Baseline-dependency: How genotype and signaled delays influence amphetamine's effects on delay discountingJournal Name: Pharmacology Biochemistry and BehaviorPublisher: Elsevier BVVol: 199Issue #:Start Page: 173070End Page: 173070Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.pbb.2020.173070Citation Count: 10
-
OPENTitle: Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s diseaseJournal Name: Journal of Biopharmaceutical StatisticsPublisher: Informa UK LimitedVol: 35Issue #: 5Start Page: 981End Page: 1000Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/10543406.2023.2170400Best OA location URL: https://doi.org/10.1080/10543406.2023.2170400Citation Count: 8
- Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient2017RESTRICTEDTitle: Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease PatientJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 40Issue #: 5Start Page: 233End Page: 234Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0000000000000230Citation Count: 7
-
OPENTitle: TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populationsJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page: 348End Page: 348Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-025-01180-zBest OA location URL: https://www.nature.com/articles/s41531-025-01180-z_reference.pdfCitation Count: 4
-
OPENTitle: A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related DisordersJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 14Issue #: 6Start Page: 1105End Page: 1114Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-230257Best OA location URL: https://doi.org/10.3233/jpd-230257Citation Count: 5
-
OPENTitle: The patient-specific mouse model with Foxg1 frameshift mutation provides insights into the pathophysiology of FOXG1 syndromeJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 16Issue #: 1Start Page: 4760End Page: 4760Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/s41467-025-59838-4Best OA location URL: https://www.nature.com/articles/s41467-025-59838-4.pdfCitation Count: 4
-
OPENTitle: Longitudinal characterization of clinical, developmental, and behavioral phenotypes in 101 children and adults with FOXG1 syndromeJournal Name: Journal of Neurodevelopmental DisordersPublisher: Springer Science and Business Media LLCVol: 17Issue #: 1Start Page: 64End Page: 64Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1186/s11689-025-09653-1Best OA location URL: https://jneurodevdisorders.biomedcentral.com/counter/pdf/10.1186/s11689-025-09653-1Citation Count: 3
-
OPENTitle: Design considerations for C9orf72 disease prevention trialsJournal Name: BrainPublisher: Oxford University Press (OUP)Vol: 148Issue #: 11Start Page: 3844End Page: 3855Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1093/brain/awaf290Best OA location URL: https://academic.oup.com/brain/advance-article-pdf/doi/10.1093/brain/awaf290/63960980/awaf290.pdfCitation Count: 2
-
OPENTitle: Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 5Issue #: 11Start Page: 917End Page: 923Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(06)70579-8Best OA location URL: http://orbilu.uni.lu/handle/10993/17148Citation Count: 82
- Oxidative Damage in Parkinson's Disease2005RESTRICTEDTitle: Oxidative Damage in Parkinson's DiseaseJournal Name: Antioxidants & Redox SignalingPublisher: SAGE PublicationsVol: 7Issue #: 5-6Start Page: 627End Page: 629Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1089/ars.2005.7.627Citation Count: 27
-
OPENTitle: Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III TrialJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 7Issue #: 4Start Page: 685End Page: 693Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-171199Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd171199?id=journal-of-parkinsons-disease%2Fjpd171199Citation Count: 20
-
OPENTitle: Dystrophin-associated protein scaffolding in brain requires α-dystrobrevinJournal Name: NeuroReportPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 21Issue #: 10Start Page: 695End Page: 699Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1097/wnr.0b013e32833b0a3bBest OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/2889226Citation Count: 15
- Biomarkers in Parkinson‘s Disease: A Funder‘s Perspective2010RESTRICTEDTitle: Biomarkers in Parkinson‘s Disease: A Funder‘s PerspectiveJournal Name: Biomarkers in MedicinePublisher: Informa UK LimitedVol: 4Issue #: 5Start Page: 723End Page: 729Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.2217/bmm.10.89Citation Count: 16
-
OPENTitle: Review of the Effects of Lifestyle Modification on Parkinson’s DiseaseJournal Name: American Journal of Lifestyle MedicinePublisher: SAGE PublicationsVol:Issue #:Start Page: 15598276251384591End Page: 15598276251384591Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1177/15598276251384591Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/15598276251384591?download=trueCitation Count: 2
- Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson’s Disease2016OPENTitle: Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson’s DiseaseJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 7Issue #: 1Start Page: 89End Page: 94Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3233/jpd-161031Citation Count: 15
-
OPENTitle: Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confoundingJournal Name: Annals of EpidemiologyPublisher: Elsevier BVVol: 35Issue #:Start Page: 42End Page: 47.e1Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.annepidem.2019.04.010Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/8074509Citation Count: 13
- Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation2020OPENTitle: Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 PhosphorylationJournal Name: Journal of Visualized ExperimentsPublisher: MyJove CorporationVol:Issue #: 157Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3791/58956Citation Count: 12
- Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review2018RESTRICTEDTitle: Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart ReviewJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 41Issue #: 5Start Page: 156End Page: 159Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0000000000000296Citation Count: 12
-
OPENTitle: The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson DiseaseJournal Name: CellsPublisher: MDPI AGVol: 9Issue #: 8Start Page: 1878End Page: 1878Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/cells9081878Best OA location URL: https://www.mdpi.com/2073-4409/9/8/1878/pdf?version=1597644425Citation Count: 6
-
OPENTitle: Promoting Physical Activity Among Immigrant Asian Americans: Results from Four Community Health Worker StudiesJournal Name: Journal of Immigrant and Minority HealthPublisher: Springer Science and Business Media LLCVol: 25Issue #: 2Start Page: 291End Page: 305Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s10903-022-01411-yBest OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/11520280Citation Count: 4
-
OPENTitle: Forecasts for the Attainment of Major Research Milestones in Parkinson’s DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 10Issue #: 3Start Page: 1047End Page: 1055Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3233/jpd-201933Best OA location URL: https://doi.org/10.17863/cam.52302Citation Count: 4
-
OPENTitle: Parkinson’S Disease is Ready for Precision MedicineJournal Name: Personalized MedicinePublisher: Informa UK LimitedVol: 13Issue #: 5Start Page: 405End Page: 407Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.2217/pme-2016-0052Best OA location URL: https://www.futuremedicine.com/doi/pdf/10.2217/pme-2016-0052Citation Count: 7
- How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease2026RESTRICTEDTitle: How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein DiseaseJournal Name: Annals of NeurologyPublisher: WileyVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/ana.78250Citation Count: 0
- PPMI 2.O New Science/New Cohorts - Transforming PPMI (2490)2020RESTRICTEDTitle: PPMI 2.O New Science/New Cohorts - Transforming PPMI (2490)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 94Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.94.15_supplement.2490Citation Count: 7